Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000935
Chunk: 57

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 57
---
, could not then be satisfied.

(c) At
any time after the Commencement Date, the Company shall have the option to terminate this Agreement for any reason or for no reason by
delivering notice (a “”) to the Investor electing to terminate this Agreement without any
liability whatsoever of any party to any other party under this Agreement (except as set forth below). The Company Termination Notice
shall not be effective until one (1) Business Day after it has been received by the Investor, and is subject to the Company having satisfied
all of its pending Purchase Share (if any) and any Commitment Share delivery obligations, and any other obligations, prior to the termination
date.

(d) This
Agreement shall automatically terminate on the date that the Company sells and the Investor purchases (including by payment of the applicable
Fixed Purchase Price, VWAP Purchase Price or Additional VWAP Purchase Price, as the case may be) the full Available Amount as provided
herein, without any action or notice on the part of any party and without any liability whatsoever of any party to any other party under
this Agreement (except as set forth below).

(e) If,
for any reason or for no reason, the full Available Amount has not been purchased in accordance with of this Agreement
by the Maturity Date, this Agreement shall automatically terminate on the Maturity Date, without any action or notice on the part of any
party and without any liability whatsoever of any party to any other party under this Agreement (except as set forth below).

Except as set forth in (in
respect of a Suspension Event under , and 10(h)), and , any termination of
this Agreement pursuant to this shall be effected by written notice from the Company to the Investor, or the Investor
to the Company, as the case may be, setting forth the basis for the termination hereof. The representations and warranties and covenants
of the Company and the Investor contained in , , , and hereof, the indemnification provisions
set forth in hereof and the agreements and covenants set forth in , and shall survive
the execution and delivery of this Agreement and any termination of this Agreement. No termination of this Agreement shall (i) affect
the Company’s or the Investor’s rights or obligations under (A) this Agreement with respect to pending Fixed Purchases, VWAP
Purchases or Additional VWAP Purchases and the Company and the Investor shall complete their respective obligations with respect to any
pending Fixed Purchases,